Estradiol valerate/dienogest

Drugs

Volumn 62, Issue 3, 2002, Pages 491-504

  Wellington, Keri ^a   Perry, Caroline M ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC GMP; DIENOGEST; DIENOGEST PLUS ESTRADIOL VALERATE; ESTRADIOL; ESTRADIOL PLUS ESTRIOL PLUS NORETHISTERONE ACETATE; ESTRADIOL PLUS NORETHISTERONE ACETATE; ESTROGEN; GESTAGEN; GLUCOCORTICOID RECEPTOR; MINERALOCORTICOID RECEPTOR; NANDROLONE; PROGESTERONE; PROGESTERONE RECEPTOR; PROSTACYCLIN DERIVATIVE; SEROTONIN DERIVATIVE; SEX HORMONE BINDING GLOBULIN; SOMATOMEDIN C; THROMBOXANE DERIVATIVE; UNCLASSIFIED DRUG; URODILATIN;

ABDOMINAL PAIN; AREA UNDER THE CURVE; BREAKTHROUGH BLEEDING; CLINICAL TRIAL; DRUG ACTIVITY; DRUG ADSORPTION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG TOLERABILITY; ENDOMETRIUM HYPERPLASIA; FEMALE; HEADACHE; HORMONE SUBSTITUTION; HUMAN; HYPERANDROGENISM; HYPERTENSION; MASTALGIA; METRORRHAGIA; MIGRAINE; NONHUMAN; OSTEOPOROSIS; POSTMENOPAUSE; REVIEW; THRUSH; TREATMENT OUTCOME; WEIGHT GAIN;

EID: 0036195489     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200262030-00006     Document Type: Review

References (47)

1. Hormone replacement therapy
2. Vasomotor flushes in menopausal women
3. Benefits and risks of hormone replacement therapy (HRT)
4. Hormone replacement therapy and endometrial cancer risk
5. The menopause
6. Estrogens and progestins
7. Lafamme®: A new oral preparation for continuous combined hormone replacement therapy in postmenopausal women
8. Dienogest as a progestin for hormone replacement therapy
9. Estradiol and dydrogesterone: A review of their combined use as hormone replacement therapy in postmenopausal women
10. Dienogest
11. The preclinical and clinical profile of dienogest. A short overview
12. Toxicology of dienogest
13. Pharmacokinetic and pharmacological features of estradiol valerate
14. Effect on biochemical vasoactive markers during postmenopausal hormone replacement therapy: Estradiol versus estradiol/dienogest
15. Comparison of the efficacy and endometrial safety of two estradiol valerate/dienogest combinations and Kliogest® for continuous combined hormone replacement therapy in postmenopausal women
16. Effects of a combination of 2 mg estradiol valerate and 3 mg dienogest on coagulation, lipid profile, and glucose metabolism in postmenopausal women
17. Insomnia related to postmenopausal syndrome: Sleep laboratory studies on differences between patients and normal controls, and influence of an estrogen-progestogen combination with dienogest versus estrogen alone and placebo
18. Double-blind, placebo-controlled psychometric studies on the effects of a combined estrogen-progestin regimen versus estrogen alone on performance, mood and personality of menopausal syndrome patients
19. Source of estrogen production in postmenopausal women
20. Ovaries
21. Pharmacokinetics of oestrogens and progestogens
22. Climodien® (estradiol valerate 2 mg plus dienogest 2 mg) is safe and effective in the treatment of postmenopausal complaints
23. A 19-norprogestin without 17α-ethinyl group I: Dienogest from a pharmacokinetic point of view
24. A 19-norprogestin without 17α-ethinyl group II: Dienogest from a pharmacodynamic point of view
25. Animal studies on the endocrinological profile of dienogest, a novel synthetic steroid
26. The clinical recording of anti-androgenic effects of dienogest
27. Pharmacokinetics of estradiol valerate 2mg + dienogest 2mg (Climodien™ 2/2) after single and repeated oral administration in healthy postmenopausal women
28. Influence of STS 557 on the mitotic activity in the endometrium of ovariectomized mice and comparison with the effects of progesterone and levonorgestrel
29. Effects of antifertility estrogens and progestins on the endometrial surface of early pregnant rats: A scanning electron microscope study
30. The influence of dienogest on ovulation in younger women and on chosen endocrinological parameters
31. Die wirkung von dienogest auf die hypothalamisch-hypophysäre achse: Ergebnisse einer pilotstudie
32. Dienogest: Bindungsstudien an verschiedenen rezeptor- und serum-proteinen
33. Progestagenic and antigonadotrophic activities of STS 557
34. STS 557, a new orally active progestin with antiprogestational and contragestational properties in rabbits
35. Zur problematik der transformationsdosenbestimmung von gestagenen
36. Dienogest, a novel synthetic steroid, overcomes hormone-dependent cancer in a different manner than progestins
37. Bioequivalence of dienogest as a single component and dienogest in combination with estradiol valerate after single administration to healthy postmenopausal women
38. Open, randomised, crossover study evaluating the relative bioavailability of estradiol valerate and dienogest administered orally as a fixed combination in comparison with a microcrystalline suspension in postmenopausal women
39. Pharmacokinetics of dienogest as a single drug or in combination with estradiol valerate or ethinylestradiol
40. β-estradiol
41. Differences in the cytochrome P-450 isoenzymes involved in the 2-hydroxylation of oestradiol and 17α-ethinyloestradiol. Relative activities of rat and human liver enzymes
42. Tissue-specific synthesis and oxidative metabolism of estrogens
43. The influence of ethinylestradiol (EE) containing contraceptives in combination with dienogest (DNG) or levonorgestrel (LNG) on cytochrome P450IIIA4 in vivo
44. The influence of a new sexual steroid-dienogest - On the metabolism of caffeine and metamizol
45. The influence of dienogest on the human cytochrome P450 enzyme system in vitro: Dienogest, preclinical and clinical results of a new progestin
46. Continuous-combined treatment of the menopause with combinations of oestradiol valerate and dienogest: A dose-ranging study